Anna E Bollag, Tianyang Guo, Ke-Hong Ding, Vivek Choudhary, Xunsheng Chen, QIng Zhong, Jianrui Xu, Kanglun Yu, Mohamed E Awad, Mohammed Elsalanty, Maribeth H Johnson, Meghan E McGee-Lawrence, Wendy B Bollag, Carlos M Isales
Osteoporosis, low bone mass that increases fracture susceptibility, affects approximately 75 million individuals in the United States, Europe and Japan, with the number of osteoporotic fractures expected to increase by more than 3-fold over the next 50 years. Bone mass declines with age, although the mechanisms for this decrease are unclear. Aging enhances production of reactive oxygen species, which can affect bone formation and breakdown. The multiple sclerosis drug Tecfidera contains dimethylfumarate, which is rapidly metabolized to monomethylfumarate (MMF); MMF is thought to function through nuclear factor erythroid-derived-2-like-2 (Nrf2), a transcription factor activated by oxidative stress which induces the expression of endogenous anti-oxidant systems...
July 1, 2019: Journal of Endocrinology